Emergent BioSolutions initiates Phase 2 study to evaluate BioThrax Emergent BioSolutions announced the initiation of a Phase 2 study designed to evaluate non-interference of BioThrax when administered in conjunction with antibiotics. This non-interference study will be used to support a supplemental Biologics License Application seeking licensure of a Post-Exposure Prophylaxis indication for BioThrax to be used in combination with antibiotics in people suspected to have been exposed to anthrax spores. The primary objective of this Phase 2 study is to evaluate any impact of the vaccine on ciprofloxacin by administering the antibiotic prior to and following the administration of a 3-dose series of BioThrax. Preliminary data from this study are expected in the fourth quarter of 2013.
News For EBS From The Last 14 Days
Check below for free stories on EBS the last two weeks.